A  ||| S:0 E:2 ||| DT
pilot  ||| S:2 E:8 ||| NN
cohort  ||| S:8 E:15 ||| NN
study  ||| S:15 E:21 ||| NN
to  ||| S:21 E:24 ||| TO
assess  ||| S:24 E:31 ||| VB
the  ||| S:31 E:35 ||| DT
feasibility  ||| S:35 E:47 ||| NN
of  ||| S:47 E:50 ||| IN
HIV  ||| S:50 E:54 ||| NNP
prevention  ||| S:54 E:65 ||| NN
science  ||| S:65 E:73 ||| NN
research  ||| S:73 E:82 ||| NN
among  ||| S:82 E:88 ||| IN
men  ||| S:88 E:92 ||| NNS
who  ||| S:92 E:96 ||| WP
have  ||| S:96 E:101 ||| VBP
sex  ||| S:101 E:105 ||| NN
with  ||| S:105 E:110 ||| IN
men  ||| S:110 E:114 ||| NNS
in  ||| S:114 E:117 ||| IN
Dakar ||| S:117 E:122 ||| NNP
,  ||| S:122 E:124 ||| ,
Senegal  ||| S:124 E:132 ||| NNP
Men  ||| S:132 E:136 ||| NNPS
who  ||| S:136 E:140 ||| WP
have  ||| S:140 E:145 ||| VBP
sex  ||| S:145 E:149 ||| NN
with  ||| S:149 E:154 ||| IN
men  ||| S:154 E:158 ||| NNS
( ||| S:158 E:159 ||| -LRB-
MSM ||| S:159 E:162 ||| NNP
)  ||| S:162 E:164 ||| -RRB-
are  ||| S:164 E:168 ||| VBP
disproportionately  ||| S:168 E:187 ||| RB
burdened  ||| S:187 E:196 ||| VBN
by  ||| S:196 E:199 ||| IN
HIV  ||| S:199 E:203 ||| NNP
in  ||| S:203 E:206 ||| IN
Senegal ||| S:206 E:213 ||| NNP
,  ||| S:213 E:215 ||| ,
across  ||| S:215 E:222 ||| IN
sub-Saharan  ||| S:222 E:234 ||| NNP
Africa  ||| S:234 E:241 ||| NNP
and  ||| S:241 E:245 ||| CC
throughout  ||| S:245 E:256 ||| IN
the  ||| S:256 E:260 ||| DT
world ||| S:260 E:265 ||| NN
.  ||| S:265 E:267 ||| .
This  ||| S:267 E:272 ||| DT
is  ||| S:272 E:275 ||| VBZ
driven  ||| S:275 E:282 ||| VBN
in  ||| S:282 E:285 ||| IN
part  ||| S:285 E:290 ||| NN
by  ||| S:290 E:293 ||| IN
stigma ||| S:293 E:299 ||| NN
,  ||| S:299 E:301 ||| ,
and  ||| S:301 E:305 ||| CC
limits  ||| S:305 E:312 ||| NNS
health  ||| S:312 E:319 ||| NN
achievements  ||| S:319 E:332 ||| NNS
and  ||| S:332 E:336 ||| CC
social  ||| S:336 E:343 ||| JJ
capital  ||| S:343 E:351 ||| NN
among  ||| S:351 E:357 ||| IN
these  ||| S:357 E:363 ||| DT
populations ||| S:363 E:374 ||| NNS
.  ||| S:374 E:376 ||| .
To  ||| S:376 E:379 ||| TO
date ||| S:379 E:383 ||| NN
,  ||| S:383 E:385 ||| ,
there  ||| S:385 E:391 ||| EX
is  ||| S:391 E:394 ||| VBZ
a  ||| S:394 E:396 ||| DT
limited  ||| S:396 E:404 ||| JJ
understanding  ||| S:404 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
the  ||| S:421 E:425 ||| DT
feasibility  ||| S:425 E:437 ||| NN
of  ||| S:437 E:440 ||| IN
prospective  ||| S:440 E:452 ||| JJ
HIV  ||| S:452 E:456 ||| NNP
prevention  ||| S:456 E:467 ||| NN
studies  ||| S:467 E:475 ||| NNS
among  ||| S:475 E:481 ||| IN
MSM  ||| S:481 E:485 ||| NNP
in  ||| S:485 E:488 ||| IN
Senegal ||| S:488 E:495 ||| NNP
,  ||| S:495 E:497 ||| ,
including  ||| S:497 E:507 ||| VBG
HIV  ||| S:507 E:511 ||| NNP
incidence  ||| S:511 E:521 ||| NN
and  ||| S:521 E:525 ||| CC
cohort  ||| S:525 E:532 ||| JJ
retention  ||| S:532 E:542 ||| NN
rates ||| S:542 E:547 ||| NNS
.  ||| S:547 E:549 ||| .
One  ||| S:549 E:553 ||| CD
hundred  ||| S:553 E:561 ||| CD
and  ||| S:561 E:565 ||| CC
nineteen  ||| S:565 E:574 ||| JJ
men  ||| S:574 E:578 ||| NNS
who  ||| S:578 E:582 ||| WP
reported  ||| S:582 E:591 ||| VBD
having  ||| S:591 E:598 ||| VBG
anal  ||| S:598 E:603 ||| JJ
sex  ||| S:603 E:607 ||| NN
with  ||| S:607 E:612 ||| IN
another  ||| S:612 E:620 ||| DT
man  ||| S:620 E:624 ||| NN
in  ||| S:624 E:627 ||| IN
the  ||| S:627 E:631 ||| DT
past  ||| S:631 E:636 ||| JJ
12  ||| S:636 E:639 ||| CD
months  ||| S:639 E:646 ||| NNS
were  ||| S:646 E:651 ||| VBD
randomly  ||| S:651 E:660 ||| RB
selected  ||| S:660 E:669 ||| VBN
from  ||| S:669 E:674 ||| IN
a  ||| S:674 E:676 ||| DT
sampling  ||| S:676 E:685 ||| JJ
frame  ||| S:685 E:691 ||| NN
of  ||| S:691 E:694 ||| IN
450  ||| S:694 E:698 ||| CD
unique  ||| S:698 E:705 ||| JJ
members  ||| S:705 E:713 ||| NNS
of  ||| S:713 E:716 ||| IN
community  ||| S:716 E:726 ||| NN
groups  ||| S:726 E:733 ||| NNS
serving  ||| S:733 E:741 ||| VBG
MSM  ||| S:741 E:745 ||| NNP
in  ||| S:745 E:748 ||| IN
Dakar ||| S:748 E:753 ||| NNP
.  ||| S:753 E:755 ||| .
These  ||| S:755 E:761 ||| DT
men  ||| S:761 E:765 ||| NNS
were  ||| S:765 E:770 ||| VBD
enrolled  ||| S:770 E:779 ||| VBN
in  ||| S:779 E:782 ||| IN
a  ||| S:782 E:784 ||| DT
15-month  ||| S:784 E:793 ||| JJ
pilot  ||| S:793 E:799 ||| NN
cohort  ||| S:799 E:806 ||| NNS
study  ||| S:806 E:812 ||| VBP
implemented  ||| S:812 E:824 ||| VBN
by  ||| S:824 E:827 ||| IN
a  ||| S:827 E:829 ||| DT
community-based  ||| S:829 E:845 ||| JJ
partner ||| S:845 E:852 ||| NN
.  ||| S:852 E:854 ||| .
The  ||| S:854 E:858 ||| DT
study  ||| S:858 E:864 ||| NN
included  ||| S:864 E:873 ||| VBD
a  ||| S:873 E:875 ||| DT
structured  ||| S:875 E:886 ||| JJ
survey  ||| S:886 E:893 ||| NN
instrument  ||| S:893 E:904 ||| NN
and  ||| S:904 E:908 ||| CC
biological  ||| S:908 E:919 ||| JJ
testing  ||| S:919 E:927 ||| NN
for  ||| S:927 E:931 ||| IN
HIV ||| S:931 E:934 ||| NNP
,  ||| S:934 E:936 ||| ,
syphilis  ||| S:936 E:945 ||| NN
and  ||| S:945 E:949 ||| CC
hepatitis  ||| S:949 E:959 ||| NNP
B  ||| S:959 E:961 ||| NNP
virus  ||| S:961 E:967 ||| NN
at  ||| S:967 E:970 ||| IN
two  ||| S:970 E:974 ||| CD
time  ||| S:974 E:979 ||| NN
points ||| S:979 E:985 ||| NNS
.  ||| S:985 E:987 ||| .
Baseline  ||| S:987 E:996 ||| NNP
HIV  ||| S:996 E:1000 ||| NNP
prevalence  ||| S:1000 E:1011 ||| NN
was  ||| S:1011 E:1015 ||| VBD
36.0 ||| S:1015 E:1019 ||| CD
%  ||| S:1019 E:1021 ||| NN
( ||| S:1021 E:1022 ||| -LRB-
43 ||| S:1022 E:1024 ||| CD
/ ||| S:1024 E:1025 ||| CD
114 ||| S:1025 E:1028 ||| CD
) ||| S:1028 E:1029 ||| -RRB-
,  ||| S:1029 E:1031 ||| ,
with  ||| S:1031 E:1036 ||| IN
cumulative  ||| S:1036 E:1047 ||| JJ
HIV  ||| S:1047 E:1051 ||| NNP
prevalence  ||| S:1051 E:1062 ||| NN
at  ||| S:1062 E:1065 ||| IN
study  ||| S:1065 E:1071 ||| NN
end  ||| S:1071 E:1075 ||| NN
being  ||| S:1075 E:1081 ||| VBG
47.2 ||| S:1081 E:1085 ||| CD
%  ||| S:1085 E:1087 ||| NN
( ||| S:1087 E:1088 ||| -LRB-
51 ||| S:1088 E:1090 ||| CD
/ ||| S:1090 E:1091 ||| CD
108 ||| S:1091 E:1094 ||| CD
) ||| S:1094 E:1095 ||| -RRB-
.  ||| S:1095 E:1097 ||| .
The  ||| S:1097 E:1101 ||| DT
annualized  ||| S:1101 E:1112 ||| JJ
incidence  ||| S:1112 E:1122 ||| NN
rate  ||| S:1122 E:1127 ||| NN
was  ||| S:1127 E:1131 ||| VBD
16 ||| S:1131 E:1133 ||| CD
%  ||| S:1133 E:1135 ||| NN
( ||| S:1135 E:1136 ||| -LRB-
8 ||| S:1136 E:1137 ||| CD
/ ||| S:1137 E:1138 ||| CD
40  ||| S:1138 E:1141 ||| CD
at  ||| S:1141 E:1144 ||| IN
risk  ||| S:1144 E:1149 ||| NN
for  ||| S:1149 E:1153 ||| IN
seroconversion  ||| S:1153 E:1168 ||| NN
over  ||| S:1168 E:1173 ||| IN
15  ||| S:1173 E:1176 ||| CD
months  ||| S:1176 E:1183 ||| NNS
of  ||| S:1183 E:1186 ||| IN
follow-up ||| S:1186 E:1195 ||| NNP
,  ||| S:1195 E:1197 ||| ,
95 ||| S:1197 E:1199 ||| CD
%  ||| S:1199 E:1201 ||| NN
confidence  ||| S:1201 E:1212 ||| NN
interval  ||| S:1212 E:1221 ||| VBD
4.6-27.4 ||| S:1221 E:1229 ||| CD
% ||| S:1229 E:1230 ||| NN
) ||| S:1230 E:1231 ||| -RRB-
.  ||| S:1231 E:1233 ||| .
Thirty-seven  ||| S:1233 E:1246 ||| JJ
men  ||| S:1246 E:1250 ||| NNS
were  ||| S:1250 E:1255 ||| VBD
lost  ||| S:1255 E:1260 ||| VBN
to  ||| S:1260 E:1263 ||| TO
follow  ||| S:1263 E:1270 ||| VB
up ||| S:1270 E:1272 ||| RP
,  ||| S:1272 E:1274 ||| ,
including  ||| S:1274 E:1284 ||| VBG
at  ||| S:1284 E:1287 ||| IN
least  ||| S:1287 E:1293 ||| JJS
four  ||| S:1293 E:1298 ||| CD
deaths ||| S:1298 E:1304 ||| NNS
.  ||| S:1304 E:1306 ||| .
Men  ||| S:1306 E:1310 ||| NNS
who  ||| S:1310 E:1314 ||| WP
were  ||| S:1314 E:1319 ||| VBD
able  ||| S:1319 E:1324 ||| JJ
to  ||| S:1324 E:1327 ||| TO
confide  ||| S:1327 E:1335 ||| VB
in  ||| S:1335 E:1338 ||| IN
someone  ||| S:1338 E:1346 ||| NN
about  ||| S:1346 E:1352 ||| IN
health ||| S:1352 E:1358 ||| NN
,  ||| S:1358 E:1360 ||| ,
emotional  ||| S:1360 E:1370 ||| JJ
distress  ||| S:1370 E:1379 ||| NN
and  ||| S:1379 E:1383 ||| CC
sex  ||| S:1383 E:1387 ||| NN
were  ||| S:1387 E:1392 ||| VBD
less  ||| S:1392 E:1397 ||| RBR
likely  ||| S:1397 E:1404 ||| JJ
to  ||| S:1404 E:1407 ||| TO
be  ||| S:1407 E:1410 ||| VB
HIV  ||| S:1410 E:1414 ||| JJ
positive  ||| S:1414 E:1423 ||| JJ
( ||| S:1423 E:1424 ||| -LRB-
OR  ||| S:1424 E:1427 ||| NNP
0.36 ||| S:1427 E:1431 ||| NNP
,  ||| S:1431 E:1433 ||| ,
p  ||| S:1433 E:1435 ||| CD
< ||| S:1435 E:1437 ||| SYM
0.05 ||| S:1437 E:1441 ||| CD
,  ||| S:1441 E:1443 ||| ,
95 ||| S:1443 E:1445 ||| CD
%  ||| S:1445 E:1447 ||| NN
CI  ||| S:1447 E:1450 ||| NNP
0.13 ||| S:1450 E:1454 ||| CD
,  ||| S:1454 E:1456 ||| ,
0.97 ||| S:1456 E:1460 ||| CD
) ||| S:1460 E:1461 ||| -RRB-
.  ||| S:1461 E:1463 ||| .
High  ||| S:1463 E:1468 ||| NNP
HIV  ||| S:1468 E:1472 ||| NNP
prevalence  ||| S:1472 E:1483 ||| NN
and  ||| S:1483 E:1487 ||| CC
incidence ||| S:1487 E:1496 ||| NN
,  ||| S:1496 E:1498 ||| ,
as  ||| S:1498 E:1501 ||| RB
well  ||| S:1501 E:1506 ||| RB
as  ||| S:1506 E:1509 ||| IN
mortality  ||| S:1509 E:1519 ||| NN
in  ||| S:1519 E:1522 ||| IN
this  ||| S:1522 E:1527 ||| DT
young  ||| S:1527 E:1533 ||| JJ
population  ||| S:1533 E:1544 ||| NN
of  ||| S:1544 E:1547 ||| IN
Senegalese  ||| S:1547 E:1558 ||| NNP
MSM  ||| S:1558 E:1562 ||| NNP
indicate  ||| S:1562 E:1571 ||| VBP
a  ||| S:1571 E:1573 ||| DT
public  ||| S:1573 E:1580 ||| JJ
health  ||| S:1580 E:1587 ||| NN
emergency ||| S:1587 E:1596 ||| NN
.  ||| S:1596 E:1598 ||| .
Moreover ||| S:1598 E:1606 ||| RB
,  ||| S:1606 E:1608 ||| ,
given  ||| S:1608 E:1614 ||| VBN
the  ||| S:1614 E:1618 ||| DT
high  ||| S:1618 E:1623 ||| JJ
burden  ||| S:1623 E:1630 ||| NN
of  ||| S:1630 E:1633 ||| IN
HIV  ||| S:1633 E:1637 ||| NNP
and  ||| S:1637 E:1641 ||| CC
rate  ||| S:1641 E:1646 ||| NN
of  ||| S:1646 E:1649 ||| IN
incident  ||| S:1649 E:1658 ||| NN
HIV  ||| S:1658 E:1662 ||| NN
infections ||| S:1662 E:1672 ||| NNS
,  ||| S:1672 E:1674 ||| ,
this  ||| S:1674 E:1679 ||| DT
population  ||| S:1679 E:1690 ||| NN
appears  ||| S:1690 E:1698 ||| VBZ
to  ||| S:1698 E:1701 ||| TO
be  ||| S:1701 E:1704 ||| VB
appropriate  ||| S:1704 E:1716 ||| JJ
for  ||| S:1716 E:1720 ||| IN
the  ||| S:1720 E:1724 ||| DT
evaluation  ||| S:1724 E:1735 ||| NN
of  ||| S:1735 E:1738 ||| IN
novel  ||| S:1738 E:1744 ||| NN
HIV  ||| S:1744 E:1748 ||| NNP
prevention ||| S:1748 E:1758 ||| NN
,  ||| S:1758 E:1760 ||| ,
treatment  ||| S:1760 E:1770 ||| NN
and  ||| S:1770 E:1774 ||| CC
care  ||| S:1774 E:1779 ||| NN
approaches ||| S:1779 E:1789 ||| NNS
.  ||| S:1789 E:1791 ||| .
Using  ||| S:1791 E:1797 ||| VBG
a  ||| S:1797 E:1799 ||| DT
study  ||| S:1799 E:1805 ||| NN
implemented  ||| S:1805 E:1817 ||| VBN
by  ||| S:1817 E:1820 ||| IN
community-based  ||| S:1820 E:1836 ||| JJ
organizations ||| S:1836 E:1849 ||| NNS
,  ||| S:1849 E:1851 ||| ,
there  ||| S:1851 E:1857 ||| EX
appears  ||| S:1857 E:1865 ||| VBZ
to  ||| S:1865 E:1868 ||| TO
be  ||| S:1868 E:1871 ||| VB
feasibility  ||| S:1871 E:1883 ||| VBN
in  ||| S:1883 E:1886 ||| IN
implementing  ||| S:1886 E:1899 ||| VBG
interventions  ||| S:1899 E:1913 ||| NNS
addressing  ||| S:1913 E:1924 ||| VBG
the  ||| S:1924 E:1928 ||| DT
multiple  ||| S:1928 E:1937 ||| JJ
levels  ||| S:1937 E:1944 ||| NNS
of  ||| S:1944 E:1947 ||| IN
HIV  ||| S:1947 E:1951 ||| NNP
risk  ||| S:1951 E:1956 ||| NN
among  ||| S:1956 E:1962 ||| IN
MSM  ||| S:1962 E:1966 ||| NNP
in  ||| S:1966 E:1969 ||| IN
this  ||| S:1969 E:1974 ||| DT
setting ||| S:1974 E:1981 ||| NN
.  ||| S:1981 E:1983 ||| .
However ||| S:1983 E:1990 ||| RB
,  ||| S:1990 E:1992 ||| ,
low  ||| S:1992 E:1996 ||| JJ
retention  ||| S:1996 E:2006 ||| NN
across  ||| S:2006 E:2013 ||| IN
arms  ||| S:2013 E:2018 ||| NNS
of  ||| S:2018 E:2021 ||| IN
this  ||| S:2021 E:2026 ||| DT
pilot  ||| S:2026 E:2032 ||| NN
intervention ||| S:2032 E:2044 ||| NN
,  ||| S:2044 E:2046 ||| ,
and  ||| S:2046 E:2050 ||| CC
in  ||| S:2050 E:2053 ||| IN
the  ||| S:2053 E:2057 ||| DT
cohort ||| S:2057 E:2063 ||| NN
,  ||| S:2063 E:2065 ||| ,
will  ||| S:2065 E:2070 ||| MD
need  ||| S:2070 E:2075 ||| VB
to  ||| S:2075 E:2078 ||| TO
be  ||| S:2078 E:2081 ||| VB
addressed  ||| S:2081 E:2091 ||| VBN
for  ||| S:2091 E:2095 ||| IN
larger-scale  ||| S:2095 E:2108 ||| JJ
efficacy  ||| S:2108 E:2117 ||| JJ
trials  ||| S:2117 E:2124 ||| NNS
to  ||| S:2124 E:2127 ||| TO
be  ||| S:2127 E:2130 ||| VB
feasible ||| S:2130 E:2138 ||| JJ
.  ||| S:2138 E:2140 ||| .
